series-a
Stage
1
Investors
About
Epirium Bio develops orally bioavailable small molecule therapies targeting PGE-2 signaling to treat neuromuscular, inflammatory, and fibrotic diseases, with its lead compound MF-300 currently in Phase 2b trials for sarcopenia.
Explore Epirium Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.